Study identifier:D9289R00001
ClinicalTrials.gov identifier:NCT06633536
EudraCT identifier:N/A
CTIS identifier:N/A
Real-life treatment outcomes of ravulizumab in Polish patients with paroxysmal nocturnal hemoglobinuria (PNH). Prospective and retrospective, multicenter, non-interventional study.
Paroxysmal nocturnal haemoglobinuria
Phase 4
No
Ravulizumab
All
40
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2025 by AstraZeneca
AstraZeneca
-
The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.
PNH-RECORD study aims to aims to collect data on the patients’ characteristics and clinical outcomes of ravulizumab administered in the scope of routine clinical practice in PNH.
Location
Status
Location
Lodz, Poland
Status
Not yet recruiting
Location
Warsaw, Poland
Status
Not yet recruiting
Location
Bialystok, Poland
Status
Not yet recruiting
Location
Lublin, Poland
Status
Not yet recruiting
Location
Brzozow, Poland
Status
Not yet recruiting
Location
Wroclaw, Poland
Status
Not yet recruiting
Location
Opole, Poland
Status
Recruiting
Location
Walbrzych, Poland
Status
Not yet recruiting
Arms | Assigned Interventions |
---|---|
Ravulizumab group Open-label | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.